A patient came in for her three-month reassessment last fall feeling 80% better than she did at the start. Sleep was solid. Energy was steady. The brain fog was gone. She told me — half joking — that she did not see why we needed the follow-up labs. She felt fine.
We ran the labs anyway. Her estradiol had climbed higher than I wanted it. Her free testosterone, which we had been targeting, had overshot the upper end of the female range. Her SHBG had dropped, which amplified the effective free hormone level beyond what the totals alone suggested. She felt great, and her physiology was already drifting toward a state that, left unadjusted for another six months, would have produced acne, hair pattern changes, and a different set of complaints. We dropped her testosterone dose by a third and rechecked at six weeks. She still felt great. The labs landed where they should.
That is what the three-month reassessment is for. Not paperwork. Not formality. The actual calibration of the dose to the actual physiology of the actual patient.
Why three months is the right window — not earlier, not later
The choice of three months as the first reassessment point is not arbitrary. It is built around the pharmacokinetics and the physiology of how the body responds to exogenous hormones.
For injectable testosterone cypionate, steady-state serum levels are reached after about five half-lives of the ester — which works out to roughly six to eight weeks of consistent dosing. For pellet-delivered hormones, the release curve stabilizes at a similar timeframe. For topical preparations, the variable is dermal absorption consistency, which also takes weeks to settle into a reproducible pattern. Reassessing earlier than ten to twelve weeks gives you a snapshot before the system has stabilized — the data is real, but it does not represent where the patient will actually live on that dose.
Three months also matches the timeline on which downstream effects begin to register. Receptor sensitivity, SHBG levels, and the conversion-to-estradiol pathway all shift in response to hormone restoration over weeks to months. The labs at three months capture not just the serum hormone levels but the system's adaptive response to those levels, which is what determines how the patient actually feels.
Reassessing later than three months is not necessarily wrong, but it costs you a quarter of a year of suboptimal calibration. Patients who feel only modestly better at month three are often patients who need a dose adjustment — and the data needed to make that adjustment correctly is the three-month panel. Waiting until month six to find out the dose was 30% too low is six months of opportunity lost.
The mechanism: why hormones do not behave like simple drugs
Most medications a primary care provider prescribes operate on a relatively linear dose-response curve. Increase the dose, increase the effect. Hormones do not work like that, and this is the single most important concept patients need to understand about why titration matters.
Hormones are signaling molecules. They bind to receptors. The number of receptors, the sensitivity of those receptors, and the binding-protein system that determines how much hormone is actually free to act — all of these adapt in response to the hormone level itself. Push the level too high and the receptors downregulate. Push it too low and the receptors upregulate but the signaling never gets loud enough to produce the downstream effect. The optimal level is the level that matches the receptor sensitivity in that specific patient at that specific point in their physiology.
The other layer is conversion. Testosterone aromatizes to estradiol at a rate that depends on body fat, age, genetic enzyme variants, and the testosterone level itself. A given dose of testosterone produces a different ratio of testosterone to estradiol in different patients, and that ratio matters as much as the absolute testosterone level. The three-month panel measures both, plus SHBG, plus the calculated free fractions — which is what tells me whether the dose is producing the hormonal environment I am trying to produce.
For estrogen and progesterone in women, the same principles apply. The serum estradiol level is one piece of information; the symptom response, the SHBG, the thyroid-binding globulin, and the progesterone ratio together tell me whether the protocol is calibrated.
The exact panel I run at three months
The three-month panel is not a cut-down version of the initial panel. It includes:
- Total testosterone, free testosterone (calculated), SHBG
- Estradiol, sensitive estradiol assay if the standard runs ambiguous
- Progesterone (in women on cyclic or continuous progesterone protocols)
- DHEA-sulfate
- LH and FSH if endogenous production status matters for the protocol
- Full thyroid: TSH, free T3, free T4, reverse T3 — because hormone optimization frequently shifts thyroid binding and conversion
- Hematocrit and hemoglobin — non-negotiable for any patient on testosterone
- Lipid panel including ApoB
- Fasting insulin, HbA1c, glucose if metabolic status was part of the initial picture
- PSA in men where age and history warrant
- hs-CRP if inflammation was part of the initial picture
I order this panel six to ten days before the reassessment visit so the data is on the desk when we sit down. The visit is not for waiting on labs. It is for going through them together.
What I look for at the three-month visit
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
When I sit down with the three-month panel and the patient's symptom report side by side, I am running through a specific list of questions:
Did the dose produce the target serum level? This is the most basic check, and it fails more often than people expect. Patients miss doses, apply topical hormones inconsistently, get pellet absorption that does not match the predicted curve, or have an absorption pattern that diverges from average. If the dose did not produce the level, we figure out why before changing the dose.
Did the level produce the symptom response? Some patients are at a perfect serum level and still do not feel right. That tells me to look at the adjacent factors — thyroid, sleep architecture, cortisol, nutritional status — that may be limiting the response. The hormone is not always the bottleneck.
Has anything else shifted that the dose was not designed for? Hematocrit drift on testosterone, estradiol elevation that needs management, SHBG shifts that change the effective free fraction, lipid changes — these are the things I am looking for before they become problems.
Are the patient's stated goals consistent with the dose's effects? Sometimes the patient and I had a conversation at the start that no longer fits where they are three months in. Goals shift. The plan has to shift with them.
Is anything happening clinically that we did not expect? Acne, mood changes, sleep disruption, water retention, breast tenderness, libido patterns — the symptom report tells me what the labs alone cannot.
The conversation that comes out of that review either confirms the protocol or adjusts it. Most three-month visits produce a small adjustment. A meaningful minority produce a significant adjustment. A small percentage end with the patient deciding the protocol is not what they want, and we either modify the approach or stop. All of those outcomes are legitimate.
What patients sometimes get wrong about the reassessment
Two patterns I see consistently in patients new to data-driven hormone care:
The first: assuming feeling good means the dose is right. Feeling good is necessary but not sufficient. The labs are what tell me whether the level is sustainable, whether the conversion ratio is healthy, whether the secondary markers are tracking where they should. A patient who feels great on a dose that is producing a hematocrit of 53% feels great until they have a thrombotic event. The labs are the early warning.
The second: treating the reassessment as optional. The patients who skip the three-month panel are the patients who, at six or nine months, end up with problems that would have been caught earlier. I will not refill a hormone protocol indefinitely without the lab cadence, and patients should be skeptical of any clinic that does. The follow-up is the medicine.
Where the reassessment fits across the broader plan
For most of my hormone therapy patients, the three-month reassessment is the first checkpoint of a long-term clinical relationship. If hormone optimization is part of the plan, the reassessment is the calibration. If men's testosterone replacement is the protocol, the same three-month cadence applies, with hematocrit, PSA, and estradiol getting particular attention. For patients on Biote pellet therapy, the timing of pellet reinsertion is itself driven by the three-month data.
Patients whose plans include medical weight loss alongside hormone optimization usually have the metabolic markers reassessed on the same panel — fasting insulin, HbA1c, lipid panel, body composition by DEXA when indicated. The systems are linked, and reassessing them in parallel is more efficient and more clinically useful than running them on separate cycles.
The next step
If you are starting hormone therapy with us — at the Columbus location or the Warner Robins location — the three-month reassessment is built into the treatment plan from day one. You leave the start-of-treatment visit with the appointment for the reassessment already on the calendar. There is no opting out and no extra step required to make sure it happens.
If you are currently on hormone therapy from another provider and have not had a comprehensive reassessment in more than six months, that is the visit to book. Bring whatever lab work you have, your current protocol details (medication, dose, delivery, schedule), and a written list of how you are feeling — what is better, what is not, what has changed since you started. We will run the relevant labs and sit down together once the data is back. Book a consultation at either location, or use the comprehensive lab work entry point if you are not sure which consultation type fits.
The reassessment is not bureaucracy. It is the only way the dose ever actually gets right. A patient on a calibrated protocol — calibrated by data, not by guess — is the patient who continues to feel well a year, three years, ten years in. That is the standard the three-month visit exists to maintain.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.